Please Wait
Applying Filters...

Annual Sales of Umeclidinium reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 193,644Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Anoro Ellipta

02 8Incruse Ellipta

03 5Trelegy Ellipta

PharmaCompass

01

Brand Name : Trelegy Ellipta

Umeclidinium Bromide

arrow
AAPS 2024
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 1,135

2019 Revenue in Millions : 718

Growth (%) : 58

blank

02

Brand Name : Incruse Ellipta

Umeclidinium

arrow
AAPS 2024
Not Confirmed

Brand Name : Incruse Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 305

2019 Revenue in Millions : 363

Growth (%) : -16

blank

03

Brand Name : Anoro Ellipta

Umeclidinium

arrow
AAPS 2024
Not Confirmed

Brand Name : Anoro Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 758

2019 Revenue in Millions : 713

Growth (%) : 6

blank

04

Brand Name : Trelegy Ellipta

Umeclidinium Bromide

arrow
AAPS 2024
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium Bromide

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 1,647

2020 Revenue in Millions : 1,122

Growth (%) : 49

blank

05

Brand Name : Anoro Ellipta

Umeclidinium

arrow
AAPS 2024
Not Confirmed

Brand Name : Anoro Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 682

2020 Revenue in Millions : 749

Growth (%) : -8

blank

06

Brand Name : Incruse Ellipta

Umeclidinium

arrow
AAPS 2024
Not Confirmed

Brand Name : Incruse Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 277

2020 Revenue in Millions : 301

Growth (%) : -7

blank

07

Brand Name : Incruse Ellipta

Umeclidinium

arrow
AAPS 2024
Not Confirmed

Brand Name : Incruse Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 242

2021 Revenue in Millions : 277

Growth (%) : -13

blank

08

Brand Name : Anoro Ellipta

Umeclidinium

arrow
AAPS 2024
Not Confirmed

Brand Name : Anoro Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 595

2021 Revenue in Millions : 682

Growth (%) : -13

blank

09

Brand Name : Trelegy Ellipta

Umeclidinium Bromide

arrow
AAPS 2024
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium Bromide

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 2,132

2021 Revenue in Millions : 1,647

Growth (%) : 29

blank

10

Brand Name : Trelegy Ellipta

Umeclidinium Bromide

arrow
AAPS 2024
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
AAPS 2024
Not Confirmed

Umeclidinium Bromide

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 2,377

2022 Revenue in Millions : 2,132

Growth (%) : 27

blank